Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
353
resultados
Última actualización
25/07/2026 [07:57:00]
Resultados 75 a 100 de 353
Resumen de: US20260194540A1
The invention relates to antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with frontotemporal dementia (FTD), but not TDP-43 associated with amyotrophic lateral sclerosis (ALS) or TDP-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with ALS, but not TDP-43 associated FTD or TDP-43 associated with healthy human brain tissue.
Resumen de: US20260193347A1
0000 The invention provides antibodies that specifically bind GPR158 and inhibit GAP activity of GPR158 via RGS7/Gβ5. The antibodies are useful in the diagnosis and treatment of affective disorders, mood disorders, and brain disorders.
Resumen de: US20260194516A1
0000 The invention is based on a novel technology to identify inflammatory responsive elements (IREs) in a mesenchymal stromal cell (MSC) culture that allowed for the development of biomarkers, in particular CD55, CD146, CD271 and MSCA-1, or combinations thereof. The biomarkers of the invention are indicative for an immunomodulatory activity of an MSC. Consequently, the present invention pertains a first aspect, to a method for determining a presence or absence of an immunomodulatory activity of a mesenchymal stromal cell (MSC). Furthermore, in a second aspect, a method for the manufacture of an immunomodulatory preparation derived from an MSC with immunomodulatory activity is disclosed. In a third and fourth aspect, the invention pertains to an immunomodulatory preparation derived from an MSC with immunomodulatory activity and its medical use. In further aspects, the invention also pertains to methods for identifying an immunomodulatory population and an immunomodulatory subpopulation of MSCs with a known presence and/or expression of a biomarker respectively, and to an agent for determining a presence or absence of an immunomodulatory activity of an MSC.
Resumen de: US20260191428A1
0000 A tool for collection of exhaled breath includes a microreactor for capturing and concentrating target compounds in a gaseous sample, such as exhaled breath. An airflow of exhaled breath enters the interior of the microreactor, then contacts the central area of the microreactor and is redirected radially outwards, passing through microfluidic channels formed between micropillars, and exits the microreactor through a plurality of vent holes at the periphery. The micropillars are coated with a capture material, such as a reactive compound capable of forming adducts with carbonyl-containing VOCs. The captured target compounds may then be eluted from the micropillars and analyzed for detection of disease states or other purposes.
Resumen de: WO2026144428A1
Provided are an scFv antibody that specifically binds Aβ, an isolated nucleic acid encoding the antibody, a vector comprising the nucleic acid, a cell comprising the isolated nucleic acid or the vector, a method for preparing the scFv antibody that specifically binds Aβ, and a use of the scFv antibody that specifically binds Aβ in the preparation of a medicament for treating Alzheimer's disease.
Resumen de: AU2024411321A1
The present disclosure describes methods comprising obtaining a level of a biomarker in a subject and based on the level of the biomarker in the subject, continuing a short chain fatty acid therapy. The disclosed methods can comprise administering a composition comprising at least one short chain fatty acid. The disclosed methods can be used to treat an inflammatory condition, a skin disorder, or an autoimmune disorder.
Resumen de: AU2024398768A1
Assays for detecting the level of soluble UNC5C in a biological fluid sample from a patient, and the use of such levels as markers of neurodegenerative disease presence and/or severity are described. Antibodies and fragments thereof capable of binding to UNC5C, and the use of such antibodies for detecting the level of soluble UNC5C in a biological fluid sample from a patient are also described, as well as methods for detecting the level of soluble UNC5C in a biological fluid sample from a patient using anti-UNC5C antibodies in a clinical context.
Resumen de: US20260193314A1
A ratiometric fluorescent sensor constructed based on a G protein-coupled receptor and its construction method are provided. It is discovered that by introducing a mutation at the same amino acid site (the third amino acid of the N-terminal linker) on a GRAB sensor, the GRAB sensor can be endowed with excitation ratiometric properties. The sensor with excitation ratiometric properties have high pH sensitivity, are not limited by the sensor's own expression level or external hardware conditions, maintain high stability of fluorescence brightness, can minimize fluorescence interference caused by motion, can sensitively detect neurotransmitter release, and have the potential for in vivo quantitative detection of neurotransmitter concentration.
Resumen de: US20260191820A1
0000 Provided herein are methods and compositions utilizing a urolithin A agent and a fisetin agent for treatment of neurodegenerative diseases.
Resumen de: US20260191829A1
0000 Pharmaceutical compositions containing a dopamine Putamen reuptake inhibitor or a dopaminergic agonist, an adrenoceptor antagonist, and a pharmaceutically acceptable carrier, and methods for treating neurological diseases by administering the composition.
Resumen de: WO2024263558A1
Described are dual transporters and methods of making and using the dual transporters. The dual transporters bind to a blood brain barrier transport protein and a second protein that is expressed on the luminal surface of the blood brain barrier or is a brain retention protein. The dual transporters improve delivery to the central nervous system.
Resumen de: WO2025046049A1
The present invention relates to molecules that are capable of binding to amyloid fibril aggregates. The invention further describes methods for detecting the presence of amyloid fibril aggregates in a sample or a subject. The invention even further describes methods for treating pathologies caused by amyloid fibril aggregates.
Resumen de: CN122344254A
0001 本发明提供了一种识别ApoE的兔源单克隆抗体，属于生物工程和生物检测技术领域。该单克隆抗体记为HZK31，包括HZK31‑B0002、HZK31‑B0005、HZK31‑B0007、HZK31‑B0011。本发明制备的兔源单克隆抗体可以高效特异性地识别人源ApoE。相比于小鼠或大鼠，本发明的兔源单克隆抗体结构更简单，具有更高的亲和力，更易于人源化。
Resumen de: WO2020172645A1
Provided is a system for detecting a user of a bathroom. The system comprises at least one sensor coupled to a bathroom use analysis device, where the sensor generates data that can be used to detect and/or identify the user. Also provided is a method of detecting a user of a bathroom. The method comprises analyzing data generated by the sensor in the above system to detect and/or identify the user.
Resumen de: CN122344252A
本申请公开了一种p‑Tau231特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用，属于免疫分析技术领域。本申请抗体重链CDRH1‑CDRH3的氨基酸序列分别依次如SEQ ID NO：1‑SEQ ID NO：3所示，轻链CDRL1的氨基酸序列如SEQ ID NO：4所示，轻链CDRL2的氨基酸序列为QA，轻链CDRL3的氨基酸序列如SEQ ID NO：5所示。本申请还提供了靶向p‑Tau231的抗体、检测p‑Tau231的化学发光试剂盒。本申请抗体亲和力高、灵敏度高且生产周期明显缩短，更适合作为核心原料应用于体外诊断试剂领域，可用于阿尔茨海默症的辅助诊断。
Resumen de: KR20260105078A
본 발명은 다채널 멀티 카트리지 고감도 면역분석 시스템에 관한 것으로, 특히 광산화 증폭을 이용하여 소량의 혈액 샘플로 질병을 파악하되, 하나의 질병에 대하여 다중 바이오마커를 이용하여 정밀하고 정확하게 현장에서 진단할 수 있는 다채널 멀티 카트리지 고감도 면역분석 시스템에 관한 것이다.
Resumen de: KR20260104904A
0001a 본 발명은 펩타이드 리간드 코팅 팁에 관한 것으로, 특히 광산화 증폭 면역 분석 기기에 사용되는 펩타이드 리간드를 안정적이고 효율적으로 코팅할 수 있는 팁을 제공하는 것이다.
Resumen de: KR20260104836A
0001a 본 발명은 2채널 고감도 면역분석 자동화 기기에 관한 것으로, 특히 광산화 증폭을 이용하여 소량의 혈액 샘플로 질병을 파악하되, 퇴행성 뇌질환과 심혈관 질환을 동시에 현장에서 진단할 수 있는 2채널 고감도 면역분석 자동화 기기에 관한 것이다.
Resumen de: CN122326739A
本发明公开了血清标志物miR‑206在制备阿尔茨海默病诊断产品中的应用，本发明首次将血清标志物miR‑206用于阿尔茨海默病的有效诊断与辅助诊断中，并且具有极高的诊断性能。本发明为开发稳定、可靠的阿尔茨海默病即时检测试剂盒或自动化化学发光检测系统等体外诊断产品奠定了技术与数据基础，具有推动阿尔茨海默病早期筛查、辅助诊断从依赖复杂影像和脑脊液检查向便捷、无创的血液检测转变的重大临床应用前景。
Resumen de: CN122325600A
本发明提供一种用于诊断阿尔茨海默症的抗体及其制备方法。申请人通过研究发现了几组抗体对，利用双抗夹心法检测p‑Tau217，亲和力和灵敏度高，对阿尔茨海默症的诊断具有十分积极的意义。
Resumen de: WO2025120373A1
Methods of determining the potency of a human neonatal Fc receptor (FcRn) antagonist composition in inhibiting the binding of human IgG to FcRn using a competition binding assay are provided. Kits for carrying out said methods, and methods of manufacturing a FcRn antagonist composition comprising said methods of determining potency are also provided.
Resumen de: CN122330436A
0001 本发明公开了一种外泌体检测方法，包括将生物样本与裂解液混合得到样本裂解液的步骤；所述裂解液与生物样本的体积比为1:1。使用本发明中的提取外泌体和直接裂解两种方法检测TSG101和PDCD6IP浓度，所得检测结果具有较高的一致性，即本方法在提高效率的同时还具有较高的准确性。
Resumen de: CN122330416A
0001 本发明属于生物技术领域，公开了血清淀粉样P物质（SAP）作为生物标志物在制备诊断或预测射血分数保留型心力衰竭合并心房颤动（HFpEF合并AF）的产品中的应用。本发明通过构建HFpEF合并AF动物模型发现，SAP在动物模型中表达水平显著升高；在临床患者血浆样本中验证发现，HFpEF合并AF患者血浆中的SAP水平较对照组显著升高。因此，本发明通过对血浆中SAP进行定量检测，可实现对HFpEF合并AF的预测或诊断。
Resumen de: CN122325602A
本发明涉及免疫学技术领域，具体公开了一种抗Tau单克隆抗体及其应用，其重链的三个CDR区的氨基酸序列分别具有如SEQ ID NO:1、2和3所示的氨基酸序列；且其轻链的三个CDR区的氨基酸序列分别具有如SEQ ID NO:4、5和6所示的氨基酸序列。本发明提供的抗Tau单克隆抗体能够结合Tau蛋白N端投射区域，特异性识别Tau蛋白N端Thr95/Thr101磷酸化修饰位点，能用于人脑样本中Tau蛋白及其病理相关组分的免疫印迹检测，能用于转基因动物和人脑组织样本中Tau病理结构的组织学检测以及Tau蛋白相关疾病中的病理分期的研究。
Nº publicación: US20260187803A1 02/07/2026
Solicitante:
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA [US]
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Resumen de: US20260187803A1
0000 Integrated platforms, systems, and associated processes for measuring lifespan, body size and shape, activity, pathology, pigmentation/color, and multiple in vivo molecular biomarkers using multiple cameras are described. The integrated platform includes a plate and trays supported on the plate. Each tray can hold animals. The integrated platform also includes an imaging module with a first camera and a second camera. The first camera can capture first images associated with movement of the animals and the second camera can capture second images and third images associated with biomarkers of the animals.
BOPI
Sede Electrónica
